Refine Search
(12)
(14)
(14)
(14)

Cardiovascular Diseases

The total revenue from branded cardiovascular drugs in 2017 is projected to be just over $40 billion. Top companies in this space are putting a heavy focus on the anti-thrombotic segment, as these drugs continue to bring in the biggest profit and dominate the cardiovascular market. Bayer currently holds the top spot in the market with 2017 sales of $5.4 billion; however, Sanofi and BMS come in a close second and third with sales of $5.1 and $4.7 billion, respectively.

Stroke - Pipeline Review, H2 2018

  • $2,000
  • September 2018
Add to Basket Quick View Add to Saved List

Global Markets Direct’s, ‘Stroke - Pipeline Review, H2 2018’, provides an overview of the Stroke pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Stroke, complete with analysis b...

Atherosclerosis - Pipeline Review, H2 2018

  • $2,000
  • September 2018
Add to Basket Quick View Add to Saved List

Global Markets Direct’s, ‘Atherosclerosis - Pipeline Review, H2 2018’, provides an overview of the Atherosclerosis pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Atherosclerosi...

Critical Limb Ischemia - Pipeline Review, H2 2018

  • $2,000
  • September 2018
Add to Basket Quick View Add to Saved List

Global Markets Direct’s, ‘Critical Limb Ischemia - Pipeline Review, H2 2018’, provides an overview of the Critical Limb Ischemia pipeline landscape.

The report provides comprehensive information on the therapeutics under development for ...

Congestive Heart Failure (Heart Failure) - Pipeline Review, H2 2018

  • $2,000
  • August 2018
Add to Basket Quick View Add to Saved List

Global Markets Direct’s, ‘Congestive Heart Failure (Heart Failure) - Pipeline Review, H2 2018’, provides an overview of the Congestive Heart Failure (Heart Failure) pipeline landscape.

The report provides comprehensive information on the...

Myocardial Infarction - Pipeline Review, H2 2018

  • $2,000
  • August 2018
Add to Basket Quick View Add to Saved List

Global Markets Direct’s, ‘Myocardial Infarction - Pipeline Review, H2 2018’, provides an overview of the Myocardial Infarction pipeline landscape.

The report provides comprehensive information on the therapeutics under development for My...

Arrhythmias - Pipeline Review, H2 2018

  • $2,000
  • August 2018
Add to Basket Quick View Add to Saved List

Global Markets Direct’s, ‘Arrhythmias - Pipeline Review, H2 2018’, provides an overview of the Arrhythmias pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Arrhythmias, complete ...

Atrial Fibrillation - Pipeline Review, H2 2018

  • $2,000
  • August 2018
Add to Basket Quick View Add to Saved List

Global Markets Direct’s, ‘Atrial Fibrillation - Pipeline Review, H2 2018’, provides an overview of the Atrial Fibrillation pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Atrial...

Pulmonary Embolism - Pipeline Review, H2 2018

  • $2,000
  • August 2018
Add to Basket Quick View Add to Saved List

Global Markets Direct’s, ‘Pulmonary Embolism - Pipeline Review, H2 2018’, provides an overview of the Pulmonary Embolism pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Pulmonar...

Deep Vein Thrombosis (DVT) - Pipeline Review, H2 2018

  • $2,000
  • August 2018
Add to Basket Quick View Add to Saved List

Global Markets Direct’s, ‘Deep Vein Thrombosis (DVT) - Pipeline Review, H2 2018’, provides an overview of the Deep Vein Thrombosis (DVT) pipeline landscape.

The report provides comprehensive information on the therapeutics under developm...

Myocarditis - Pipeline Review, H2 2018

  • $2,000
  • August 2018
Add to Basket Quick View Add to Saved List

Global Markets Direct’s, ‘Myocarditis - Pipeline Review, H2 2018’, provides an overview of the Myocarditis pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Myocarditis, complete ...

Restenosis - Pipeline Review, H2 2018

  • $2,000
  • August 2018
Add to Basket Quick View Add to Saved List

Global Markets Direct’s, ‘Restenosis - Pipeline Review, H2 2018’, provides an overview of the Restenosis pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Restenosis, complete wit...

Pulmonary Arterial Hypertension - Pipeline Review, H2 2018

  • $2,000
  • August 2018
Add to Basket Quick View Add to Saved List

Global Markets Direct’s, ‘Pulmonary Arterial Hypertension - Pipeline Review, H2 2018’, provides an overview of the Pulmonary Arterial Hypertension pipeline landscape.

The report provides comprehensive information on the therapeutics unde...

Hypertension - Pipeline Review, H1 2018

  • $2,000
  • June 2018
Add to Basket Quick View Add to Saved List

Global Markets Direct’s, ‘Hypertension - Pipeline Review, H1 2018’, provides an overview of the Hypertension pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Hypertension, comple...

Myocardial Fibrosis - Pipeline Review, H1 2018

  • $2,000
  • June 2018
Add to Basket Quick View Add to Saved List

Global Markets Direct’s, ‘Myocardial Fibrosis - Pipeline Review, H1 2018’, provides an overview of the Myocardial Fibrosis pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Myocar...

Septic Shock - Pipeline Review, H2 2016

  • $2,000
  • September 2016
Add to Basket Quick View Add to Saved List

Global Markets Direct’s, ‘Septic Shock - Pipeline Review, H2 2016’, provides an overview of the Septic Shock pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Septic Shock, comple...